A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (NCT06425991)
A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants With Relapsed/Refractory Multiple Myeloma
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the pharmacokinetics (processes by which drugs are absorbed, distributed in the body, and excreted) between teclistamab made from the current commercial manufacturing process (pre-change) and the new manufacturing process (post-change).
Who can join: Review the eligibility criteria below.
Location: Banner MD Anderson Cancer Center — Gilbert, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (53 Sites)
Showing the first 25 of 53 sites.
- Banner MD Anderson Cancer Center — Gilbert, Arizona
- Colorado Blood Cancer Institute — Denver, Colorado
- Cleveland Clinic Florida — Weston, Florida
- Augusta University- Georgia Cancer Center — Augusta, Georgia
- St Francis Hospital & Health Centers Indiana Blood and Marrow Transplantation Franciscan Health — Indianapolis, Indiana
- Cleveland Clinic — Cleveland, Ohio
- Baylor University Medical Center — Dallas, Texas
- Flinders Medical Centre — Bedford Park,
- Box Hill Hospital — Box Hill,
- Royal Prince Alfred Hospital — Camperdown,
- Epworth Healthcare — Richmond,
- Cross Cancer Institute — Edmonton, Alberta
- Princess Margaret Cancer Centre University Health Network — Toronto, Ontario
- CHRU de Lille Hopital Claude Huriez — Lille,
- Hospices Civils de Lyon HCL — Lyon,
- CHU Nantes — Nantes,
- CHU de Bordeaux - Hospital Haut-Leveque — Pessac,
- Klinikum Chemnitz gGmbH — Chemnitz,
- Universitaetsklinikum Hamburg Eppendorf — Hamburg,
- Universitaetsklinikum Heidelberg — Heidelberg,
- Universitatsklinikum Wurzburg — Würzburg,
- Carmel Medical Center — Haifa,
- Hadassah University Hospita Ein Kerem — Jerusalem,
- Sheba Medical Center — Ramat Gan,
- Sourasky Medical Center — Tel Aviv,
📞 Contact the Study Coordinator
Phone: (877) 632-6789
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.